Precision medicine and personalized breast cancer: combination pertuzumab therapy

References

• American Cancer SocietyCancer Facts and Figures: 2013–2014AtlantaAmerican Cancer Society2013
   Google Scholar
• SlamonDJClarkGMWongSGLevinWJUllrichAMcGuireWLHuman breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogeneScience198723547851771823798106
   PubMed Web of Science ®Google Scholar
• CoussensLYang-FengTLLiaoYCTyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogeneScience19852304730113211392999974
   PubMed Web of Science ®Google Scholar
• KingCRKrausMHAaronsonSAAmplification of a novel v-erbB-related gene in a human mammary carcinomaScience198522947179749762992089
   PubMed Web of Science ®Google Scholar
• SchechterALSternDFVaidyanathanLThe neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigenNature198431259945135166095109
   PubMed Web of Science ®Google Scholar
• TandonAKClarkGMChamnessGCUllrichAMcGuireWLHER-2/neu oncogene protein and prognosis in breast cancerJ Clin Oncol198978112011282569032
   PubMed Web of Science ®Google Scholar
• ToikkanenSHelinHIsolaJJoensuuHPrognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-upJ Clin Oncol1992107104410481351537
   PubMed Web of Science ®Google Scholar
• SeshadriRFirgairaFAHorsfallDJMcCaulKSetlurVKitchenPClinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study GroupJ Clin Oncol19931110193619428105035
   PubMed Web of Science ®Google Scholar
• MarksJRHumphreyPAWuKOverexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancerAnn Surg199421943323417909221
   PubMed Web of Science ®Google Scholar
• PegramMDKonecnyGSlamonDThe molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancerCancer Treat Res2000103577510948442
   PubMedGoogle Scholar
• ArteagaCLSliwkowskiMXOsborneCKPerezEAPuglisiFGianniLTreatment of HER2-positive breast cancer: current status and future perspectivesNat Rev Clin Onc2012911632
   Web of Science ®Google Scholar
• AminDNCampbellMRMoasserMMThe role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeuticsSemin Cell Dev Biol201021994495020816829
   PubMed Web of Science ®Google Scholar
• BaselgaJSwainSMNovel anticancer targets: revisiting ERBB2 and discovering ERBB3Nat Rev Cancer20099746347519536107
   PubMed Web of Science ®Google Scholar
• LuYZiXZhaoYMascarenhasDPollakMInsulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)J Natl Cancer Inst200193241852185711752009
   PubMed Web of Science ®Google Scholar
• SlamonDJLeyland-JonesBShakSUse of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N Engl J Med20013441178379211248153
   PubMed Web of Science ®Google Scholar
• Piccart-GebhartMJProcterMLeyland-JonesBTrastuzumab after adjuvant chemotherapy in HER2-positive breast cancerN Engl J Med2005353161659167216236737
   PubMed Web of Science ®Google Scholar
• SlamonDEiermannWRobertNAdjuvant trastuzumab in HER2-positive breast cancerN Engl J Med2011365141273128321991949
   PubMed Web of Science ®Google Scholar
• McArthurHLMahoneyKMMorrisPGAdjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancerCancer2011117245461546821681735
   PubMed Web of Science ®Google Scholar
• RodriguesMJPeronJFrénelJSBenefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective seriesAnn Oncol201324491692423104720
   PubMed Web of Science ®Google Scholar
• Mohd SharialMSCrownJHennessyBTOvercoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancerAnn Oncol201223123007301622865781
   PubMed Web of Science ®Google Scholar
• NahtaREstevaFJHerceptin: mechanisms of action and resistanceCancer Lett2006232212313816458110
   PubMed Web of Science ®Google Scholar
• VermaSMilesDGianniLTrastuzumab emtansine for HER2-positive advanced breast cancerN Engl J Med2012367191783179123020162
   PubMed Web of Science ®Google Scholar
• FranklinMCCareyKDVajdosFFLeahyDJde VosAMSliwkowskiMXInsights into ErbB signaling from the structure of the ErbB2-pertuzumab complexCancer Cell20045431732815093539
   PubMed Web of Science ®Google Scholar
• KristjansdottirKDizonDHER-dimerization inhibitors: evaluating pertuzumab in women’s cancersExpert Opin Biol Ther201010224325020001562
   PubMed Web of Science ®Google Scholar
• ScheuerWFriessTBurtscherHBossenmaierBEndlJHasmannMStrongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor modelsCancer Res200969249330933619934333
   PubMed Web of Science ®Google Scholar
• NahtaRHungMCEstevaFJThe HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cellsCancer Res20046472343234615059883
   PubMed Web of Science ®Google Scholar
• AgusDBAkitaRWFoxWDTargeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growthCancer Cell20022212713712204533
   PubMed Web of Science ®Google Scholar
• LangdonSPFaratianDNagumoYMullenPHarrisonDJPertuzumab for the treatment of ovarian cancerExpert Opin Biol Ther20101071113112020465533
   PubMed Web of Science ®Google Scholar
• HerbstRSDaviesAMNataleRBEfficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancerClin Cancer Res200713206175618117947484
   PubMed Web of Science ®Google Scholar
• BaselgaJGelmonKAVermaSPhase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapyJ Clin Oncol20102871138114420124182
   PubMed Web of Science ®Google Scholar
• BaselgaJSwainSMCLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancerClin Breast Cancer201010648949121147694
   PubMed Web of Science ®Google Scholar
• BaselgaJCortésJKimSBPertuzumab plus trastuzumab plus docetaxel for metastatic breast cancerN Engl J Med2012366210911922149875
   PubMed Web of Science ®Google Scholar
• SwainSMKimSBCortésJPertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 studyLancet Oncol201314646147123602601
   PubMed Web of Science ®Google Scholar
• Ciruelos GilEMBrufskyAImYHEfficacy and safety of first-line (1L) pertuzumab (P), trastuzumab (T), and docetaxel (D) in HER2-positive MBC (CLEOPATRA) in patients previously exposed to trastuzumabJ Clin Oncol2013Suppl 31600
   Google Scholar
• BaselgaJCortésJImSABiomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in HER-2-positive, first-line metastatic breast cancer (MBC)Cancer Res201272Suppl 24S5S11
   Google Scholar
• GianniLLladóABianchiGOpen-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancerJ Clin Oncol20102871131113720124183
   PubMed Web of Science ®Google Scholar
• CortésJFumoleauPBianchiGVPertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancerJ Clin Oncol201230141594160022393084
   PubMed Web of Science ®Google Scholar
• BardiaABaselgaJPreoperative chemotherapy for operable breast cancerLippmanMHarrisJMonica MorrowMOsborneKDiseases of the BreastPhiladelphiaLippincott Williams & Wilkins2013
   Google Scholar
• ReynoldsKLBhatiaAChengXNeoadjuvant single and dual HER2 blockade among patients with localized HER2-positive breast cancerJ Clin Oncol201331Suppl 26147
   Web of Science ®Google Scholar
• BardiaAGreenupRMoyBPathological complete remission after neoadjuvant chemotherapy predicts improved survival in the various breast cancer subtypes: Systematic review and meta-analysesPoster presented at: AACR Advances in Breast Cancer ResearchOctober 12–15, 2011San Francisco, CA
   Google Scholar
• GianniLPienkowskiTImYHEfficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialLancet Oncol2012131253222153890
   PubMed Web of Science ®Google Scholar
• SchneeweissAChiaSHickishTNeoadjuvant pertuzumab and trastuzumab concurrent or sequential with an anthracycline-containing or concurrent with an anthracycline-free standard regimen: a randomized phase II study (TRYPHAENA)Cancer Res201171Suppl 24S5S6
   Google Scholar
• GianniLDafniUGelberRDTreatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trialLancet Oncol201112323624421354370
   PubMed Web of Science ®Google Scholar
• von MinckwitzGBaselgaJBradburyIOT1-02-04: adjuvant pertuzumab and herceptin in initial therapy of breast cancer: APHINITY (BIG 4-11/BO25126/TOC4939g)Cancer Res201171Suppl 24OT1-02-04
   Google Scholar
• AgusDBGordonMSTaylorCPhase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancerJ Clin Oncol200523112534254315699478
   PubMed Web of Science ®Google Scholar
• NgCMLumBLGimenezVKelseySAllisonDRationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysisPharm Res20062361275128416715358
   PubMed Web of Science ®Google Scholar
• Genentech Perjeta [full prescribing information]San FranciscoGenentech2012
   Google Scholar
• MotHER Pregnancy Registry Available from: http://www.herceptinpregnancyregistry.comAccessed January 16, 2014
   Google Scholar
• CroneSAZhaoYYFanLErbB2 is essential in the prevention of dilated cardiomyopathyNat Med20028545946511984589
   PubMed Web of Science ®Google Scholar
• PerezEACardiac toxicity of ErbB2-targeted therapies: what do we know?Clin Breast Cancer20088Suppl 3S114S12018777950
   PubMed Web of Science ®Google Scholar
• US Food Drug AdministrationFDA approves Perjeta for neoadjuvant breast cancer treatment [press release]Silver Spring, MDFDA9302013 Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm370393.htmAccessed October 5, 2013
   Google Scholar
• US Food Drug AdministrationPertuzumab [prescribing information] Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125409s051lbl.pdf?et_cid=32583475&et_rid=463654371&linkid=+http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2013%2f125409s051lbl.pdfAccessed on October 5, 2013
   Google Scholar
• ChernewMENewcomerLNSwainSMTreatment and cost implications of pertuzumabAm J Manag Care2012184SP151SP15323009230
   PubMed Web of Science ®Google Scholar
• BanerjiSCibulskisKRangel-EscarenoCSequence analysis of mutations and translocations across breast cancer subtypesNature2012486740340540922722202
   PubMed Web of Science ®Google Scholar
• SleijferSBogaertsJSiuLLDesigning transformative clinical trials in the cancer genome eraJ Clin Oncol201331151834184123589555
   PubMed Web of Science ®Google Scholar
• EstevaFJGuoHZhangSPTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancerAm J Pathol201017741647165620813970
   PubMed Web of Science ®Google Scholar
• HankerABPfefferleADBalkoJMMutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapiesProc Natl Acad Sci U S A201311035143721437723940356
   PubMed Web of Science ®Google Scholar
• OcanaAVera-BadilloFSerugaBTempletonAPandiellaAAmirEHER3 overexpression and survival in solid tumors: a meta-analysisJ Natl Cancer Inst2013105426627323221996
   PubMedGoogle Scholar
• MakhijaSAmlerLCGlennDClinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancerJ Clin Oncol20102871215122319901115
   PubMed Web of Science ®Google Scholar
• BerghoffASBago-HorvathZPreusserMCo-expression of HER3 in HER2-positive metastatic breast cancer patients is an independent predictor of impaired prognosisPoster presented at: European CongressSeptember 27–October 1, 2013Amsterdam, Netherlands
   Google Scholar
• BardiaABaselgaJNeoadjuvant therapy as a platform for drug development and approval in breast cancerClin Cancer Res201319236360637024298066
   PubMed Web of Science ®Google Scholar
• ProwellTMPazdurRPathological complete response and accelerated drug approval in early breast cancerN Engl J Med2012366262438244122646508
   PubMed Web of Science ®Google Scholar
• UntchMvon MinckwitzGNeoadjuvant chemotherapy: early response as a guide for further treatment: clinical, radiological, and biologicalJ Natl Cancer Inst Monogr201120114313814122043061
   PubMedGoogle Scholar
• RimawiMFMayerIAForeroAMulticenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006J Clin Oncol201331141726173123569315
   PubMed Web of Science ®Google Scholar
• DeMicheleABerryDAZujewskiJDeveloping safety criteria for introducing new agents into neoadjuvant trialsClin Cancer Res201319112817282323470967
   PubMed Web of Science ®Google Scholar
• RocheHoffmann-LaA Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer Available from: http://clinicaltrials.gov/show/NCT01358877 NLM identifier: NCT01358877Accessed December 10, 2013
   Google Scholar
• RocheHoffmann-LaA Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE) Available from: http://clinicaltrials.gov/show/NCT01120184 NLM identifier: NCT01120184Accessed December 10, 2013
   Google Scholar
• RocheHoffmann-LaA Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA) Available from: http://clinicaltrials.gov/show/NCT01026142 NLM identifier: NCT01026142Accessed December 10, 2013
   Google Scholar